TARA-002

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lymphatic Malformation

Conditions

Lymphatic Malformation

Trial Timeline

Oct 18, 2023 → May 1, 2026

NCT ID

NCT05871970

About TARA-002

TARA-002 is a phase 2 stage product being developed by Protara Therapeutics for Lymphatic Malformation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05871970. Target conditions include Lymphatic Malformation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05871970	Phase 2	Recruiting	Oct 18, 2023	May 1, 2026	Lymphatic Malformation
NCT05951179	Phase 2	Recruiting	Sep 15, 2023	Aug 1, 2030	Non-muscle Invasive Bladder Cancer
NCT05085990	Phase 1	Completed	May 8, 2023	Sep 12, 2024	Non-muscle Invasive Bladder Cancer
NCT05085977	Phase 1	Completed	Mar 10, 2022	Oct 30, 2024	Non-muscle Invasive Bladder Cancer

Competing Products

5 competing products in Lymphatic Malformation

See all competitors

Product	Company	Stage	Hype Score
AWZ1066S + Placebo	Eisai	Phase 1	33
Alpelisib + Placebo	Novartis	Phase 2/3	65
Remdesivir	Gilead Sciences	Phase 2	51
SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran	Arcturus Therapeutics	Phase 2	44
BIVV003 + ST-400	Sangamo Therapeutics	Pre-clinical	15

Other Products from Protara Therapeutics

TARA-002 + Investigator's Choice of Intravesical ChemotherapyPhase 3

Choline Chloride for Injection + PlaceboPhase 2/3

TARA-002Phase 2

TARA-002Phase 1